Your session is about to expire
← Back to Search
VIB7734 for Systemic Lupus Erythematosus (RECAST SLE Trial)
RECAST SLE Trial Summary
This trial is testing a new drug for lupus in 195 people. It will last 48 weeks, with safety follow-up for 8 more weeks. There will be 3 groups, 2 taking the drug and 1 taking placebo.
RECAST SLE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRECAST SLE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RECAST SLE Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any documented cases of people being harmed by VIB7734?
"VIB7734's safety was given a score of 2 by our analysts. This is due to the lack of data supporting efficacy, which is typical for medications in Phase 2 clinical trials."
To be eligible for this experiment, what are the required qualifications?
"This study is open to 214 patients that have been diagnosed with libman-sacks disease. The participants must be between the ages of 18 and 70 and meet the following criteria: Fulfill the 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for SLE, Disease duration of at least 6 months, SLEDAI-2K total score ≥ 6 at Screening, excluding fever, SLE headache, or organic brain syndrome., SLEDAI-2K total score ≥ 4, excluding points attributable to any urine or laboratory results, immunologic measures, fever, SLE"
Will this research be beneficial for seniors?
"The age range for patients that can enroll in this clinical trial is 18 to 70 years old. However, there are 17 other trials available for minors and 112 research studies open to senior citizens."
What is the maximum capacity for participants in this clinical trial?
"This study is not currently looking for new participants. It was posted on June 24th, 2021 and updated on August 11th, 2022. For those still interested in taking part in clinical trials, there are 128 other studies enrolling patients with libman-sacks disease and 1 trial involving VIB7734 that are actively searching for volunteers."
How can people sign up for this research project?
"Unfortunately, this clinical trial is no longer recruiting patients. The study was first posted on June 24th, 2021 and received its last update on August 11th, 2022. However, there are 128 other trials for libman-sacks disease and 1 VIB7734 study that are still looking for participants."
Are different hospitals in this city trialing this procedure?
"Enrollment for this study is available at 23 sites. Some of these locations include La Jolla, Syracuse and Greensboro. To reduce enrollee burden, please choose the nearest location to you when enrolling in the study."
What is the VIB7734 research history?
"VIB7734 was first researched in 2021 by Centro de Estudios de Investigacion Basica Y Clinica SC. So far, there have been 18290 completed trials and 1 trial that is still recruiting patients. The majority of these studies are based in La Jolla, California."
Have other similar trials been conducted in the past?
"VIB7734 was first researched in 2021 by Viela Bio. The initial study, which included 214 participants, occurred that same year. After the successful completion of Phase 2 drug approval in 2021, there is only one current and active study being conducted by Viela Bio."
Share this study with friends
Copy Link
Messenger